International Journal of Rheumatic Diseases最新文献

{"title":"Five-Year Delivery Rate and Time to Delivery Among Women With and Without Rheumatoid Arthritis: A Real-World Analysis Using a Nationwide Claims Database in Japan","authors":"Hiroshi Ohtsu,&nbsp;Izumi Fujioka,&nbsp;Mikako Goto,&nbsp;Chinatsu Takai,&nbsp;Naohiro Yonemoto,&nbsp;Kazuhiro Sase,&nbsp;Atsuko Murashima","doi":"10.1111/1756-185X.70296","DOIUrl":"https://doi.org/10.1111/1756-185X.70296","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Rheumatoid arthritis (RA) frequently affects women of reproductive age; its treatment requires disease-modifying antirheumatic drugs (DMARDs). Despite the widespread use of biologics and the expected improvement in fertility, real-world studies evaluating reproductive outcomes in women with RA are limited. We aimed to compare reproductive outcomes in women with and without RA using a nationwide claims database in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study analyzed 231 427 women (aged 20–38 years) from the JMDC Claims Database. After propensity score matching, we compared 262 women with RA (defined by diagnosis and DMARDs prescription) to 1310 matched controls without RA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During the 5-year follow-up, women with RA showed significantly lower delivery rates than the matched controls (19.0% vs. 28.2%, <i>p</i> &lt; 0.001). Kaplan–Meier analysis demonstrated a significantly longer time to delivery in the RA group than in the non-RA group (log-rank <i>p</i> = 0.0014). In the subgroup analysis, the mean time to delivery was longer in patients with RA and methotrexate use (38.1 months) than in those without methotrexate use (33.7 months) and in non-RA controls (32.2 months). Despite modern RA treatments, including biologics, women with RA have significantly lower delivery rates and longer delivery times than those without RA. This study was limited by potentially unmeasured confounding factors and the lack of certain data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings highlight the need for proactive reproductive health management in women with RA and emphasize the importance of collaboration between rheumatologists and obstetricians to provide optimal care for these patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70296","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144213754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tacrolimus Induced Abnormal Uterine Bleeding in a Patient With Systemic Lupus Erythematosus: A Case Report","authors":"Chunyan Li,&nbsp;Yu Wang,&nbsp;Yuren Wang,&nbsp;ShiYu Cui,&nbsp;YuZhuo Luo,&nbsp;Xuejiao Lou,&nbsp;Mei Tian","doi":"10.1111/1756-185X.70200","DOIUrl":"https://doi.org/10.1111/1756-185X.70200","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Xanthogranulomatous Osteomyelitis of the Femur: A Rare Mimic of Malignant Bone Tumors","authors":"Hiroshi Hatakeyama,&nbsp;Yu Mori,&nbsp;Shinichirou Yoshida,&nbsp;Jun Iwatsu,&nbsp;Hirotaka Kurata,&nbsp;Shin Hitachi,&nbsp;Mika Watanabe,&nbsp;Toshimi Aizawa","doi":"10.1111/1756-185X.70313","DOIUrl":"https://doi.org/10.1111/1756-185X.70313","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144206487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in Therapeutic Approaches and Biomarkers: A New Epoch for Sjögren's Syndrome Management","authors":"Xianfei Gao,&nbsp;Wen Tang,&nbsp;Ping Zeng","doi":"10.1111/1756-185X.70301","DOIUrl":"https://doi.org/10.1111/1756-185X.70301","url":null,"abstract":"&lt;p&gt;Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease primarily affecting exocrine glands, characterized by symptoms such as dry mouth and eyes, fatigue, and joint pain. It often accompanies other autoimmune disorders like rheumatoid arthritis and lupus [&lt;span&gt;1&lt;/span&gt;]. Despite its widespread occurrence and significant effect on quality of life, treatment strategies for pSS have traditionally been limited. These strategies have often focused on providing symptomatic relief rather than addressing the underlying disease process. pSS poses a complex challenge in the field of autoimmune disorders, particularly in terms of diagnosis and management. Traditionally, diagnosis has been reliant on clinical assessments and invasive biopsies, with therapeutic interventions limited to symptomatic relief. However, with new biomarkers and novel therapeutic strategies emerging, we are entering a new epoch in managing pSS. These advancements promise to revolutionize the field, offering targeted treatment regimens that could significantly enhance patient outcomes and quality of life [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;PSS is characterized by the infiltration of lymphocytes into exocrine glands, which leads to the destruction of glandular tissue and, consequently, functional impairment. The exact cause of the condition remains unclear; however, it is believed that genetic predisposition, environmental triggers, and abnormal immune responses may contribute to its development. PSS is often underdiagnosed or misdiagnosed due to its nonspecific symptoms and overlap with other autoimmune conditions [&lt;span&gt;3&lt;/span&gt;]. Traditional diagnostic methods, including subjective dry eye and dry mouth assessments, serological tests for autoantibodies, and salivary gland biopsy, have limitations in terms of invasiveness, specificity, and sensitivity. This underscores the urgent need for reliable, noninvasive biomarkers to improve early diagnosis, assess disease activity, and monitor therapeutic responses [&lt;span&gt;4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;In pSS, biomarkers play an essential role in early diagnosis, assessment of the severity of the disease, and prediction of the prognosis. A summary of pSS biomarkers is shown in Table 1. The presence of autoantibodies such as SSA (Ro) and SSB (La) is a hallmark of pSS, but newer autoantibodies like ANA, RF, Anti-SP-1, Anti-PSP, Anti-CA-6, Anti-AQP5, and Anti-CarPare are garnering attention for their potential role in the early diagnosis of the disease. Elevated levels of cytokines and chemokines in blood samples, such as CXCL10, IL-6, IL-17A, CXCL13, IL-14a, and BAFF (B-cell activating factor), and decreased levels of CCL28 have been linked to early diagnosis and severe conditions. These not only serve as biomarkers for disease progression but also as potential therapeutic targets. The disease biomarkers are not limited to cytokines and chemokines. Detections of gas, receptors, protein, and RNAs also showed optimum disease prediction ability. The increasin","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70301","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144206488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tuberculosis and Gout Risk","authors":"Shih-Wei Lai","doi":"10.1111/1756-185X.70312","DOIUrl":"https://doi.org/10.1111/1756-185X.70312","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144206489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory Bowel Disease and Risk of Rheumatoid Arthritis: A UK Biobank Cohort Study","authors":"Kuangyu He,&nbsp;Yi Xu,&nbsp;Zhengqiang Yuan,&nbsp;Hao Xiong,&nbsp;Yunhao Zhai,&nbsp;Juehong Li,&nbsp;Yun Qian,&nbsp;Ziyang Sun,&nbsp;Cunyi Fan","doi":"10.1111/1756-185X.70314","DOIUrl":"https://doi.org/10.1111/1756-185X.70314","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) are both prevalent inflammatory conditions within the population. Our objective was to explore the relationship between IBD and RA, while examining the role of inflammatory mediators in the observed association.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used data from the UK Biobank, a population-based prospective cohort study that recruited adults aged 37–73 years from 22 centers in England, Scotland, and Wales between 2006 and 2010. We included patients diagnosed with IBD at baseline and excluded those with RA at baseline or missing follow-up information. Cox regression proportional hazard models were employed to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) between patients with IBD (Ulcerative colitis and Crohn's disease) at baseline and the risk of RA. Additionally, we conducted mediation analysis to examine the roles of C-reactive protein (CRP) and several composite inflammatory indices as potential mediators.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After excluding participants with RA at baseline (<i>N</i> = 6769), those lacking IBD subtype information (<i>N</i> = 475), and those with missing covariate data (<i>N</i> = 121 195), a total of 373 693 individuals were included in the analysis. Compared with individuals without IBD, those with IBD had a significantly higher risk of developing RA (hazard ratio 2.06, 95% confidence interval 1.69–2.51). This association remained robust after adjustment for multiple confounders and across all major subgroups. Notably, the risk of RA associated with IBD was even higher among individuals with a low polygenic risk score for RA. Mediation analysis showed that systemic inflammatory markers, such as CRP, explained only a modest proportion of the association between IBD and RA, with the highest mediation proportion observed being 9.56%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In the UK Biobank cohort study, individuals with IBD demonstrated an increased risk of developing RA. Future research should aim to gain insight into these underlying mechanisms and explore ways to improve long-term health outcomes in these patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144206914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Effectiveness of TNF-α and IL-6 Inhibitors on Bone Health Outcomes and Mortality in Rheumatoid Arthritis Patients: A Retrospective Cohort Study","authors":"Hong Wang,&nbsp;Yun-Hen Lee,&nbsp;I-Han Cheng,&nbsp;Shiow-Ing Wang,&nbsp;Jingting Ji,&nbsp;An-Ping Huo,&nbsp;Yao-Min Hung","doi":"10.1111/1756-185X.70204","DOIUrl":"https://doi.org/10.1111/1756-185X.70204","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Rheumatoid arthritis (RA) significantly impacts bone health, leading to osteoporosis and increased fracture risks. This study aims to compare the effects of TNF-α and IL-6 inhibitors on the incidence of fractures, osteoporosis, and mortality among RA patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study using the TriNetX database, spanning from January 1, 2015, to December 31, 2022. The adult patients diagnosed with Rheumatoid Arthritis (RA) were identified and divided into two groups of new users of TNF-α and IL-6 inhibitors. Patients with prior fractures or who switched treatments post-index were excluded. Patients baseline characteristics were adjusted with propensity score matching (PSM). We compared TNF-α and IL-6 inhibitor cohorts in terms of fracture and osteoporosis incidence, and mortality employing Cox proportional hazards models for risk assessment, adjusting for potential confounders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 2158 RA patients each in the TNF-α and IL-6 cohorts after PSM. Both cohorts had 71 osteoporosis/fractures during a 1-year follow-up. The adjusted HR (95% CI) was 0.987 (0.711–1.372) comparing TNFi versus IL-6is initiators. Similar results were shown stratified by age, sex, and steroid usage. However, all-cause mortality was significantly lower in the TNF-α cohort with an adjusted HR (95% CI) of 0.247 (0.114–0.536). Subgroup analyses showed the TNF-α cohort was associated with lower all-cause mortality among patients older than 65, male patients, and steroid users.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>TNF-α and IL-6 inhibitors exhibit comparable effects on the risk of osteoporosis and fractures among RA patients. Notably, TNF-α inhibitors may offer advantages in reducing all-cause mortality, warranting further investigation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144171664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Successful Treatment of Secukinumab-Induced SAPHO Syndrome With Tofacitinib","authors":"Man Li,&nbsp;Patrick Wu,&nbsp;Su-Boon Yong,&nbsp;Pui-Ying Leong","doi":"10.1111/1756-185X.70305","DOIUrl":"https://doi.org/10.1111/1756-185X.70305","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144171669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Rituximab in Connective Tissue Disease-Associated Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy","authors":"Naoaki Ohkubo,&nbsp;Shingo Nakayamada,&nbsp;Shunsuke Fukuyo,&nbsp;Yusuke Miyazaki,&nbsp;Yoshino Inoue,&nbsp;Hiroaki Tanaka,&nbsp;Yasuyuki Todoroki,&nbsp;Yoshiya Tanaka","doi":"10.1111/1756-185X.70292","DOIUrl":"https://doi.org/10.1111/1756-185X.70292","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>This study examined the efficacy and safety of Rituximab (RTX) treatment in connective tissue disease (CTD)-associated thrombocytopenic purpura (TTP) and thrombotic microangiopathy (TMA), using historical controls as comparators.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients who were admitted to our department from March 1, 2013 to March 31, 2021, and diagnosed with CTD-associated TTP/TMA refractory to plasma exchange were included in the study. A patient with treatment-resistant disease was treated with RTX in addition to high-dose glucocorticoid (GC) therapy (GC + RTX). As historical controls, we selected patients with CTD-associated TTP/TMA who were admitted to our center and treated with GC and immunosuppressants (IS) such as cyclophosphamide. The primary endpoint was the survival rate 52 weeks after the start of treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifteen patients were enrolled in the study (GC + RTX). As a control group, 11 patients were enrolled in the same manner (GC + IS). There were no significant differences in age or sex or laboratory tests between the two groups. The primary endpoint of survival rate was significantly higher in the GC + RTX group than in the GC + IS group. In the immunophenotyping analysis before treatment, among all subsets of immune cells, only plasmocytes were significantly elevated in TTP patients compared to healthy controls. Plasmocytes correlated with serum markers, suggesting increased B cell differentiation, which was markedly decreased after RTX treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In CTD-associated TTP/TMA, B cells may affect pathology, and adding RTX to plasma exchange and GC therapy may be worth considering.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70292","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144171665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Response to Adalimumab Therapy and Its Determinants in Patients With Radiographic Axial Spondyloarthritis: A Prospective Real-World Study in Taiwan","authors":"Feng-Cheng Liu,&nbsp;Cheng-Hsun Lu,&nbsp;Chang-Fu Kuo,&nbsp;Hsien-Tzung Liao,&nbsp;Shinn-Shing Lee,&nbsp;Kuei-Ying Su,&nbsp;Wan-Yu Sung,&nbsp;Wen-Chan Tsai,&nbsp;Hsin-Hua Chen,&nbsp;Hung-An Chen,&nbsp;James Cheng-Chung Wei,&nbsp;Jui-Cheng Tseng,&nbsp;Meng-Yu Weng,&nbsp;Hsiang-Cheng Chen,&nbsp;Song-Chou Hsieh","doi":"10.1111/1756-185X.70285","DOIUrl":"https://doi.org/10.1111/1756-185X.70285","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To investigate the clinical response to adalimumab (ADA) in patients with active radiographic axial spondyloarthritis (r-axSpA) in Taiwan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this real-world study, patients with r-axSpA, starting ADA therapy, were enrolled and followed up every 12 weeks for 48 weeks. Outcome parameters were the proportion of patients with an improvement of 50% in Bath ankylosing spondylitis disease activity index (BASDAI50), inactive disease (ID, &lt; 1.3), and low disease activity (LDA, &lt; 2.1) per ankylosing spondylitis disease activity score–C-reactive protein (ASDAS-CRP) and ASDAS-erythrocyte sedimentation rate (ASDAS-ESR), and change in peripheral and extra-musculoskeletal manifestations. Determinants of BASDAI50 response to ADA were examined. Treatment-emergent adverse events (TEAEs) were recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 88 enrolled patients, 86 were analyzed, and 82 completed the study with all patients receiving 40 mg ADA fortnightly. Patients achieving BASDAI50 increased from 79.1% to 80.5% from weeks 12 to 48. At week 48, ASDAS-CRP and -ESR, ID, and LDA were improved from baseline in 60.8%, 74.7%, 42.1%, and 68.4% of patients, respectively. A decrease in enthesitis, peripheral arthritis, dactylitis, and uveitis was noted. Younger age, presence of uveitis, and use of conventional synthetic disease-modifying antirheumatic drugs were the determinants of treatment response. At least one TEAE was reported in 22.7%, serious AEs in 2.3% of patients, and no deaths. The most common TEAEs were upper respiratory tract infection (5.7%) and cough (3.4%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This real-world, prospective study in Taiwan involving patients with active r-axSpA shows that ADA treatment effectively reduced disease activity and improved physical function. No new safety concerns were noted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70285","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144171668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}